Head-To-Head Survey: Heron Therapeutics (NASDAQ:HRTX) vs. Enliven Therapeutics (NASDAQ:ELVN)

Enliven Therapeutics (NASDAQ:ELVN) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Risk and Volatility

Enliven Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.

Valuation & Earnings

This table compares Enliven Therapeutics and Heron Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$89.02 million	($1.84)	-15.31
Heron Therapeutics	$144.29 million	1.76	-$13.58 million	($0.09)	-15.39

Heron Therapeutics has higher revenue and earnings than Enliven Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Enliven Therapeutics and Heron Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-24.88%	-23.96%
Heron Therapeutics	-8.75%	N/A	-1.95%

Institutional and Insider Ownership

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Enliven Therapeutics and Heron Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1	0	4	0	2.60
Heron Therapeutics	1	1	3	0	2.40

Enliven Therapeutics presently has a consensus price target of $41.00, suggesting a potential upside of 45.53%. Heron Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 224.91%. Given Heron Therapeutics’ higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Enliven Therapeutics.

Summary

Heron Therapeutics beats Enliven Therapeutics on 7 of the 13 factors compared between the two stocks.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About Heron Therapeutics

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.